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AnaboliceffectsofPTHhavebeenobservedatseveralskeletal
sites in humans by dual x-ray absorptiometry without differ-
entiating between an actual increase in bone volume and an
increase in mineral content within already established bone.
The present study addressed this issue by evaluating the bone
mineralization density distribution of iliac crest bone biop-
sies before and after PTH treatment for 18–36 months in men
and women with osteoporosis using quantitative backscat-
tered electron imaging. In cortical bone, pairwise comparison
of the two biopsies before and after treatment revealed a re-
duction in the typical calcium concentration in men (3.32%;
P  0.02, by paired t test), but no change in women, and the
heterogeneity of mineralization increased in both males and
females [18.80% (P  0.09) and 18.14% (P  0.005), respec-
tively]. In cancellous bone, there was no change in the typical
calcium concentration, but there was a greater heterogeneity
of mineralization in both men and women [19.65% (P  0.02)
and 21.59% (P  0.056), respectively] due to newly formed
bone matrix. Small angle x-ray scattering performed on a sub-
groupofsubjectsrevealednormalcollagen/mineralstructure.
The findings confirm the observations that PTH stimulates
skeletal remodeling, resulting in an increased percentage of
newly formed bone matrix of lower mineral density. (J Clin
Endocrinol Metab 88: 1150–1156, 2003)
A
LBRIGHT (1) ORIGINALLY demonstrated that para-
thyroid extract was anabolic to the skeletons of ro-
dents. These findings were confirmed in humans in a series
of small, mostly uncontrolled studies performed about 20 yr
ago with the modest amounts of human PTH-(1–34) that
could be synthesized (2). Early biopsy data suggested large
increases in cancellous bone of the iliac crest. Recent data
have shown much more modest increases in cancellous bone
on biopsy (3, 4). However, large increases in bone mineral
density (BMD), particularly in the spine have been observed
using dual energy x-ray absorptiometry (DXA) (5–7).
Smaller, but still impressive, increases in BMD by DXA have
been observed with agents acting to suppress bone remod-
eling, particularly the bisphosphonates. A recent study of
mineralization density has suggested that most, if not all, of
the increase observed using DXA can be explained by an
increased degree of mineralization and not by an increased
amount of bone tissue (8, 9). The discrepancy results because
DXA cannot differentiate between bone that has become
more highly mineralized and a greater amount of normally
mineralized bone.
Although PTH stimulates remodeling, it is not clear
whether the discrepancy between the modest changes seen
in biopsies and the greater increases observed with DXA are
related to alterations in mineral distribution. To examine this
issue we have examined iliac crest biopsies from patients
before and after administration of daily sc PTH [human (h)
PTH-(1–34)] using quantitative backscattered electron imag-
ing to evaluate calcium distribution within the bone. In a
subgroupofsubjectswealsoperformedscanningsmallangle
x-ray scattering to examine mineral particle size and align-
ment. The combination of these two quantitative techniques
allows evaluation of alterations in the quality of the bone
compositematerialanddifferentiationofthesechangesfrom
alterations in the true mass of tissue.
Materials and Methods
Samples
Twenty-six iliac crest bone biopsies were obtained from 13 patients
with osteoporosis, before and after treatment with hPTH-(1–34), as pre-
viously described (3). Seven were men with idiopathic osteoporosis
(mean age, 49 yr) treated for 18 months with 25 g/d hPTH-(1–34) by
sc self-administered injection. Six were women with postmenopausal
osteoporosis, treated with the same dose of PTH for 18–36 months. All
women were receiving standard doses of hormone replacement therapy
Abbreviations: BE, Backscattered electron; BMD, bone mineral den-
sity; BMDD, bone mineralization density distribution; CaPeak, typical
calciumconcentrationinthesample;CaWidth,widthofthedistribution;
CLSM, confocal laser scanning microscopy; DXA, dual energy x-ray
absorptiometry; FWHM, full width at half maximum; hPTH, human
PTH; HRT, hormone replacement therapy; Md. BFR/BS, mineralized
boneformationrate/bonesurface;qBEI,quantitativebackscatteredelec-
tron imaging; scanning-SAXS, scanning small angle x-ray scattering.
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1150(HRT) before and during PTH treatment, and men found to be testos-
teronedeficientwerealsotreatedwithreplacementdosesoftestosterone
before and during treatment with hPTH-(1–34). Before biopsy all pa-
tients were double-labeled with tetracycline in a 3:12:3 d sequence (3).
For the first biopsy, tetracycline hydrochloride (Sumycin, 250 mg, four
timesperday,orally;Apothecon,Princeton,NJ)wasusedtoproducethe
first label, and demeclocycline hydrochloride (Declomycin, 150 mg,
four times per day, orally; Lederle Pharmaceutical, Pearl River, NY)
was used to produce the second label. The labels produced by each
tetracycline differ in color under UV light. For the second biopsy, the
order of tetracyclines was reversed to aid distinction between the two
sets of labels. Full details of the clinical trials have been published
previously (5).
Sample preparation
From the polymethylmethacrylate-embedded undecalcified iliac
crestbonebiopsies,blockswithplanoparallelsurfaceswerepreparedby
grinding and polishing, and were subsequently coated with carbon for
backscattered electron imaging in the scanning electron microscope. For
the scanning small angle x-ray scattering (scanning-SAXS) measure-
ments, 200-m-thick sections were prepared head-on from six of the
quantitative backscattered electron imaging (qBEI)-investigated blocks.
Finally, confocal laser scanning microscopy (CLSM) was performed on
one sample (from a male PTH-treated patient), which was ground to 100
m thickness. Subsequently, this 100-m-thick section was coated with
carbon, and the CLSM-studied area was analyzed by qBEI.
qBEI
qBEI was used to determine the mineral density distribution of both
cortical and cancellous bone from the biopsies. The equipment used was
a digital scanning electron microscope (DSM 962, Zeiss, Oberkochen,
Germany) equipped with a four-quadrant semiconductor backscattered
electron (BE) detector. The accelerating voltage of the electron beam was
adjusted to 20 kV, the probe current to 110 pA, and the working distance
to 15 mm. The cortical and cancellous bone areas were imaged at 50
nominal magnification, corresponding to a pixel resolution of 4 m/
pixel, using a scan speed of 100 sec/frame, resulting in digital calibrated
BE images of 512  512 pixels. The total area analyzed from each sample
was about 30 mm
2. From the digital images, gray level histograms were
deduced, displaying the percentage of bone area occupied by pixels of
a certain gray level. The transformation of these into calcium wt%
histograms led to a bin width of 0.17 wt% calcium. A technical precision
of 0.3% was achieved. Full technical details of the technique and its
precision have been published previously (10–12).
In this study two parameters were obtained from the bone mineral-
ization density distributions. The typical calcium concentration in the
sample [CaPeak; synonymous to CaMaxFreq used in previous works (9,
12)] represents the peak position in the histogram. The width of the
distribution (CaWidth), obtained as the full width at half maximum
(FWHM) and synonymous to FWHM in previous works (9, 12), is a
measure of the homogeneity of mineralization in the sample.
CSLM
Imaging of the fluorescence labeling of the biopsies was performed
using a confocal scanning laser microscope (TCS
4D, Leica Corp., Rock-
leigh, NJ).
Scanning-SAXS
Two hundred-micron-thick sections from six samples (men, before
and after PTH treatment) were cut from the blocks and examined by
scanning-SAXS. Measurements were performed using an instrument
equipped with a 12-kW rotating Cu-anode generator (CuK- radiation
  0.154 nm, operating at 40 kV/40 mA), an evacuated pinhole camera
(sample to detector distance, 1 m), and a two-dimensional, position-
sensitive,proportionalcounterwithaspatialresolutionof100m(AXS,
Karlsuhe, Germany) as described previously (13). The sample was
mounted on a sample holder that could be moved automatically with a
precision of 2 m in the plane perpendicular to the beam (diameter, 150
m). The scanning-SAXS patterns were background-corrected and an-
alyzed for the mean particle thickness parameter, T, and the degree of
alignment, , within each sample as previously described (13, 14). For
the evaluation of T, bone is considered as a two-phase system consisting
of organic matrix and mineral, differing in electron density. By defini-
tion, T is 4(1  )/, where  is the volume fraction of the particles,
and  is the surface of the particles per total volume. With particles of
typicaldimensionsa,b,c,T2(1)/(1/a1/b1/c),whichisclose
to the thickness for plate-like particles, if  is on the order of 50%. The
alignment of the particles within the x-ray beam interaction volume
causes different scanning-SAXS patterns, showing a narrow streak for
perfect parallel alignment, a spherically shaped pattern for completely
randomorientation,andanellipticalpatternforallotherconfigurations.
Therefore, the shape of the scanning-SAXS pattern can be used to de-
termine the degree of alignment () of the mineral particles, with   0
indicating no predominant orientation and   0 revealing the percent-
age of mineral particles that are not randomly aligned within the area
of the x-ray beam.
Additionally, the function G(x), which gives information on the size
distribution,shape,andalignmentofmineralparticles,wasdetermined.
G(x) is obtained from the radial average density of the scanning-SAXS
pattern, where x  qT (where q is the length of the scattering vector, and
T is the mineral particle thickness parameter) (14). The shape of the G(x)
function is characteristic for healthy human adult bone (14) and would
bealteredif,forexample,interventionresultedinmineralabnormalities.
Statistical analysis
The statistical significance of the qBEI parameters was evaluated
using a paired t test to study the mean intraindividual change caused
by PTH. Comparison of the mean values of this study and those of a
reference group of healthy individuals [described in a previous study
(9)] was performed by ANOVA, followed by Fisher’s post hoc test (Fish-
er’s protected least significant difference test). SAXS parameters were
studied by determination of changes by comparing all data obtained
before PTH treatment with posttreatment biopsy data for each of the
three patients using t test. Correlation of mineralized bone formation
rate/bone surface (Md. BFR/BS) with CaPeak and CaWidth was per-
formed using simple linear regression. P  0.05 was considered statis-
tically significant. Statistical analyses were performed using StatView
4.5 (Abacus Concepts, Inc., Berkeley, CA).
Results
We have demonstrated previously that the BMD of the
spine increased by 13% over 3 yr in women (5) and by 13.5%
over 18 months in men (6) with PTH treatment. Smaller
increments were seen in the hip, and standard histomor-
phometry also showed modest changes in bone volume in
the iliac crest (3).
qBEI
Figure 1 shows typical backscattered electron images of
cortical (A and B) and cancellous (C and D) bone before and
after PTH treatment in a male patient. In cortical bone, the
mineralization pattern becomes less homogeneous, a likely
consequence of increased Haversian remodeling. In cancel-
lous bone there is increased bone formation, shown here as
the darker gray (low mineralization density) areas at the
surface of the trabeculae. The corresponding mineralization
distribution densities are displayed in Fig. 2. It is readily
apparent that the distribution is shifted to the left (lower
mineraldensity)afterPTHtreatmentandthatthepeakwidth
is increased.
The bone mineralization density distribution parameters
were analyzed for alterations due to treatment by paired t
test (see Fig. 3). Figure 3 summarizes the mean values for
CaPeak and CaWidth before and after treatment for male
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we compared the mean value of the parameters for cancel-
lous bone with those of a reference group of healthy indi-
viduals published previously (12) (data for the reference
group not shown; see Table 1).
The baseline peak calcium concentration in cancellous
bone in the male group was significantly lower than that in
a reference population (12) (P  0.005; reference population
data not shown), in contrast to that in the female group. The
peakcalciumconcentrationincorticalbonewaslowerinmen
before treatment than in women (3.1%; P  0.041), but not
in cancellous bone. Before treatment, peak width was not
different for male or female cancellous bone compared with
the reference group, whereas it was increased vs. that for the
reference group (data not shown) after treatment (P  0.028
and P  0.056 for men and women, respectively).
In cortical bone intraindividual changes were evident in
peak calcium concentrations in men, but not in women
(3.32%;P0.02,bypairedttestformen;notsignificantfor
women). The increase in heterogeneity of mineralization in
cortical bone after treatment was 18.80% (P  0.09 not
significant) and 18.14% (P  0.005) for men and women,
respectively. In cancellous bone, treatment produced no al-
teration in the typical calcium concentration, but caused an
increase in heterogeneity of mineralization of 19.65% (P 
0.02) and 21.59% (P  0.056) for men and women,
respectively.
As the bone samples from the patients had been labeled
with tetracycline before the biopsies were obtained (3),
CLSM could be used to identify the sites of new bone for-
mation. Figure 4 shows the fluorescence labeling (A) and the
corresponding backscattered electron image (B) of the same
trabecula (male patient, after PTH administration); Fig. 4C
gives the overlay of A and B. Comparison of these two
images confirmed that very low mineralization density is
present at the bone sites, which are forming new bone tissue
during PTH treatment. CaPeak within the two labeling lines
(18.19 wt%) was approximately 27% lower than CaPeak in
adjacent interstitial bone (23.05 wt%).
Correlationsofthetwoparametersobtainedfromthebone
mineralization density distribution (BMDD) after PTH treat-
ment, peak calcium concentration and peak width, with Md.
BFR/BS (nomenclature according to Ref. 15) and osteoid
perimeter previously determined using standard histomor-
phometry (3) showed linear correlations (Fig. 5). CaPeak vs.
Md. BFR/BS resulted in R
2  0.62 (P  0.05), and CaWidth
vs. Md. BFR/BS resulted in R
2  0.97 (P  0.0001). For this
correlation, patients with a mineralizing perimeter lower
FIG. 1. A typical pair of iliac crest biopsies (from one male patient) taken before (left column) and after (right column) PTH treatment. A and
B, Cortical bone areas; C and D, cancellous bone areas.
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treatment were spread within the range of 0.02–0.12 m
2/
md (Md. BFR/BS data are taken from Ref. 3), the Md.
BFR/BS data before treatment lie within a narrow range
(0.05 m
2/md). Before treatment, no significant linear
correlation of Md. BFR/BS with CaPeak and CaWidth was
observed (data not shown). CaPeak and CaWidth vs. the
osteoidperimeterrevealedR
20.46(P0.05)andR
20.45
(P  0.05), respectively. For this correlation, one female pa-
tient had to be excluded because no osteoid perimeter data
were available for her. The same parameters, CaPeak and
CaWidth, measured before treatment did not show any sig-
nificant correlation with the osteoid perimeter (data not
shown).
Scanning-SAXS
The mean particle thickness parameter, T, in both cortical
and cancellous bone (from three male patients) was approx-
imately 3.2 nm and was not significantly altered due to
treatment, although there was a trend toward smaller par-
ticle thickness (0.4% and –2.1% for cortical and cancellous
bone, respectively). There was also a nonsignificant trend
towardpooreralignmentoftheparticlesatbothskeletalsites
(4.9% and –8.3% for cortical and cancellous bone, respec-
tively). Thickness and alignment of the particles are not
shown in the figure. The shape of the G(x) function was
normal before treatment and was not modified by treatment
with PTH (see Fig. 6) for any of the three male patients.
Discussion
We have shown in this comparison of paired iliac crest
bone biopsies before and after PTH treatment that distinct
alterations in the mineralization pattern of iliac crest bone
occur in both men and women. qBEI revealed significant
effects on the homogeneity of mineralization, but only minor
changes in the typical calcium concentration. The heteroge-
neity of mineralization was markedly increased after PTH.
This broadening of the distribution was caused by a higher
percentageoflowermineralizedbonematrixafterPTHtreat-
ment. These findings confirm the anabolic effect of PTH and
areinperfectagreementwithonepreviousanimalstudy(16).
In this work the comparison of the images, which show the
fluorescencelabeling,ontheonehand,andthebackscattered
electron signal, on the other, confirm that the broadening of
the calcium concentration peak observed after treatment is
due to the newly formed, but not yet fully mineralized, bone
matrix. This is consistent with the observed correlation of
CaPeak and CaWidth with Md. BFR/BS and osteoid
perimeter.
From the scanning-SAXS investigation we obtained infor-
mation on the collagen/mineral composite of bone. We
found that the bone matrix formed during treatment is nor-
mal;thusthereisnochangeintheG(x)function.Thisfinding
of normal particles is in contrast to the abnormalities ob-
servedaftertheadministrationofotheranabolicagents,such
as fluoride (17, 18). Scanning-SAXS also revealed no signif-
icant alterations in particle thickness and alignment after
PTH, although a trend toward smaller thickness and lower
degree of alignment (neither statistically significant, at least
in part due to the small sample size) could be observed after
treatment, in agreement with a higher proportion of less
mineralized bone suggesting less mature bone (19).
Itisinterestingtonotethatthecalciumconcentrationinthe
biopsiesbeforetreatmentwasgreaterinwomenthaninmen,
possibly due to the HRT of the women. There seems also to
be a different response to PTH in the mineralization pattern
forwomenandmeninthattheirbonecalciumconcentrations
did not change to the same degree. One explanation could
again be the antiresorptive effect of HRT in the women.
Another explanation for the differences between the re-
sponses of male and female skeletons may simply be the
longer interval of treatment and thus the more mature status
of mineralization in the skeletons of the treated women.
Whenthemineralizationpatternswerecomparedwiththose
of a reference group of healthy individuals from a previous
work (9, 12), we found lower mineralization in men in this
study.Thislowermineralizationisconsistentwiththatinthe
placebo-treated group of a previous study (9) and could be
an indication of lower mineralization in osteoporosis. How-
ever, a larger group of healthy patients (in this work n  20
for a reference group) as well as osteoporotic patients is
needed to clarify whether osteoporotic bone is less miner-
alized generally.
The shift of the BMDD toward lower mineralization den-
sity and the peak broadening are in contrast to other treat-
ments of osteoporosis that inhibit bone resorption, such as
bisphosphonates. Alendronate has been reported to increase
BMD and homogeneity (8, 9, 20). It is interesting that these
FIG. 2. The BMDD of cortical (A) and cancellous (B) bone from one
male patient (see Fig. 1). E, Before treatment; F, during PTH treat-
ment. Note the shift toward lower mineralization density and the
increased peak width after treatment.
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decreased fracture incidence. Therefore, it is very likely that
the main effect of PTH is increased bone formation and
subsequently bone volume, which contribute to the im-
proved mechanical competence of PTH-treated bone.
Another question that might be asked is what will happen
FIG. 3. CaPeak (A) and CaWidth (B) before
() and after (f) PTH treatment. The bars
represent the mean for all male (n  7) and
female (n  6) patients (mean  SE) of cortical
and cancellous bone. *, Significant difference
due to treatment (P  0.05, by paired t test).
TABLE 1. Comparison of the measured BMDD-parameters (of cancellous bone) before and after treatment with the data from cancellous
bone of a group of healthy, adult individuals from a previous study (12)
Difference to healthy control
group (from Ref. 12) P
Male patients CaPeak Before PTH 2.39% 0.005
After PTH 4.47% 0.0001
Female patients CaPeak Before PTH 0.92% n.s.
After PTH 2.17% 0.052 (n.s.)
Male patients CaWidth Before PTH 3.32% n.s.
After PTH 15.38% 0.028
Female patients CaWidth Before PTH 6.64% n.s.
After PTH 14.00% 0.056 (n.s.)
P values show the result from ANOVA test. n.s., Not significantly different from control group.
FIG. 4. CLSM image with the fluorescence labeling (A) and the corresponding BE image of the trabecula (B) from one biopsy (male patient,
after treatment). C, Overlay of A and B. Within the fluorescence-labeled lines (black arrow) CaPeak was 18.19 wt%; CaPeak of the adjacent
interstitial bone (white arrow) was 23.05 wt%.
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clear, the data presented here suggest that there may be
differencesinresponsedependinguponthedurationofPTH
treatment. Early discontinuation might result in continued
increases in BMD measured by DXA as the mineral matures.
Later withdrawal might result in a lesser change or stability
or even loss of bone mass. One recent study reported that
BMD could be maintained 1 yr after treatment with PTH for
3 yr in women receiving HRT (21, 22). One other study in
which PTH was used only for 1 yr showed increases in BMD
after PTH withdrawal enhanced by bisphosphonate treat-
ment, as might be expected (23). These observations are
consistent with the possibility that bone matrix formed dur-
ing PTH treatment matures during prolonged secondary
mineralization. Therefore, the lower calcium concentrations
seen here during PTH treatment would be expected to be
transient.
The observed change in BMDD confirms many clinical
observations,showingthatintermittentPTHstimulatesbone
formation, which results in deposition of new bone and in-
creased bone volume (5–7, 22, 24, 25). However, the reported
discrepancy in DXA (significant increase in BMD) and the
more modest changes in histomorphometry measurements
(3, 4) cannot be explained by the results of this study. In
contrast, the significant increase in BMD could be underes-
timated due to the lower mineralization as found by qBEI.
One possible explanation could be the difference in the way
the measurements are performed by these two approaches.
In DXA, exactly the same bone region (thus, the same ver-
tebra, for instance) was measured before and after treatment,
whereas histomorphometrical analysis was performed on
two biopsies containing different bone regions from each
patient, thus contributing to a greater uncertainty in the
comparisonofthemeasuredparameters.Anotherpossibility
is that there may be an interaction between the stimulation
of new bone formation by PTH and mechanical stress, such
that the PTH effect is magnified in loaded parts of the
skeleton.
From the point of material properties, the newly formed
matrix during PTH administration has been now shown by
qBEI and SAXS to reveal no abnormalities in its micro- or
nanostructure.Consequently,wecanspeculatethatthefinite
stateofmineralizationoftheformedbonematrixdependson
the overall rate of bone turnover, which is to some extent
coupled to mechanical loading by the adaptation to the me-
chanicalstresspattern.Thus,physiologicalmechanicalusage
together with antiresorptive-like estrogens and bisphospho-
nates should probably support the normalization of bone
turnover and the optimization of trabecular architecture and
BMDD. These considerations therefore suggest a triple com-
bination therapy for postmenopausal and idiopathic male
osteoporosis:normalizationofcalciummetabolismandbone
FIG. 5. The linear correlations of Md.
BFR/BS and osteoid perimeter with CaPeak
and CaWidth in male and female patients
after PTH treatment. For the correlations
with Md. BFR/BS, patients with a mineral-
izing perimeter lower than 1% were ex-
cluded. For the correlations with the osteoid
perimeter, one patient had to be excluded
because her osteoid perimeter was not avail-
able.
FIG. 6. The G(x) function obtained from scanning-SAXS reveals the
size distribution, shape, and mineral particle alignment. Typical G(x)
for trabecular bone from one patient before (E) and after (F) PTH
treatment. The solid line reveals the Lorentz function, which corre-
sponds to a broad (exponentially decreasing) size distribution of the
mineral particles as found in disturbed mineralization, e.g. in fluo-
rosis (17).
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ulation of bone formation with intermittent PTH; and con-
sequently controlled mechanical loading. Long-term obser-
vationsofPTH-treatedpatientsatthelevelofbiopsieswould
helpustoclarifythefurtherdevelopmentandmineralization
of the matrix newly formed during PTH treatment.
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